Maheswari R, Chandra Akhilesh, Agrawal Rahul
Department of Oral Pathology, Faculty of Dental Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Oral Dis. 2025 Aug 4. doi: 10.1111/odi.70048.
Adenoid cystic carcinoma (AdCC) is a rare, aggressive salivary gland malignancy with a poor prognosis due to metastasis and local recurrence. Although hypoxia-inducible factors-1/2α (HIF-1/2α) play crucial roles in AdCC, their pleiotropic effects remain poorly understood. This systematic review and meta-analysis evaluates the impact of HIF-1/2α in AdCC progression.
A comprehensive literature search was conducted across PubMed, Scopus, EMBASE, and Web of Science to identify studies examining HIF-1/2α in AdCC. Study quality was assessed using the modified Newcastle-Ottawa scale, and meta-analyses were performed using IBM SPSS Statistics (Version 29).
Sixteen studies met inclusion criteria, with 10 studies encompassing 650 AdCC cases included in the meta-analysis. Positive HIF-1/2α expression was reported in 77.4% of AdCC cases (95% CI: 0.630-0.919, p < 0.001) and was significantly correlated with tumor size (OR: 0.38, 95% CI: 0.16-0.89, p = 0.03), advanced stage (OR: 2.86, 95% CI: 1.74-4.71, p < 0.001), and distant metastasis (OR: 1.82, 95% CI: 1.02-3.25, p = 0.04). Human studies demonstrated significantly increased HIF-1/2α protein and mRNA expression in AdCC cases compared to control groups. Solid-type AdCC exhibited predominantly higher nuclear HIF-1α expression than cribriform and tubular subtypes. Additionally, in cell culture models, the hypoxia-induced upregulation of these factors increased the expression of VEGF (20-fold), BNIP3 (6-fold), and NID1, promoting angiogenesis, epithelial-mesenchymal transition, autophagy, and invasiveness.
HIF-1/2α emerge as a pivotal drivers of AdCC progression, serving dual roles as prognostic biomarker and therapeutic target, necessitating further clinical investigation through multicenter validation studies.
腺样囊性癌(AdCC)是一种罕见的侵袭性唾液腺恶性肿瘤,由于转移和局部复发,预后较差。尽管缺氧诱导因子-1/2α(HIF-1/2α)在腺样囊性癌中起关键作用,但其多效性作用仍知之甚少。本系统评价和荟萃分析评估了HIF-1/2α在腺样囊性癌进展中的影响。
在PubMed、Scopus、EMBASE和Web of Science上进行了全面的文献检索,以确定研究腺样囊性癌中HIF-1/2α的研究。使用改良的纽卡斯尔-渥太华量表评估研究质量,并使用IBM SPSS Statistics(版本29)进行荟萃分析。
16项研究符合纳入标准,其中10项研究共650例腺样囊性癌病例纳入荟萃分析。77.4%的腺样囊性癌病例报告HIF-1/2α表达阳性(95%CI:0.630-0.919,p<0.001),且与肿瘤大小显著相关(OR:0.38,95%CI:0.16-0.89,p=0.03)、晚期(OR:2.86,95%CI:1.74-4.71,p<0.001)和远处转移(OR:1.82,95%CI:1.02-3.25,p=0.04)。人体研究表明,与对照组相比,腺样囊性癌病例中HIF-1/2α蛋白和mRNA表达显著增加。实体型腺样囊性癌的核HIF-1α表达主要高于筛状和管状亚型。此外,在细胞培养模型中,缺氧诱导的这些因子上调增加了VEGF(20倍)、BNIP3(6倍)和NID1的表达,促进了血管生成、上皮-间质转化、自噬和侵袭。
HIF-1/2α是腺样囊性癌进展的关键驱动因素,作为预后生物标志物和治疗靶点发挥双重作用,需要通过多中心验证研究进行进一步的临床研究。